Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21

Documenti analoghi

• Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
  di: Annels, Nicola E., et al.
  Pubblicazione: (2018)
• Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
  di: Pandha, Hardev, et al.
  Pubblicazione: (2015)
• Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
  di: Annels, Nicola E., et al.
  Pubblicazione: (2020)
• Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
  di: Simpson, G R, et al.
  Pubblicazione: (2012)
• Oncolytic Viruses: Time to Compare, Contrast, and Combine?: 5th International Meeting on Replicating Oncolytic Virus Therapeutics Banff, Alberta, Canada, 18–22 March 2009
  di: Pandha, Hardev, et al.
  Pubblicazione: (2009)